Top

Published in:

01-05-2024 | Olanzapine | Review

2020 ASCO, 2023 NCCN, 2023 MASCC/ESMO, and 2019 CCO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in cancer patients

Authors: Samantha K. F. Kennedy, Shannon Goodall, Shing Fung Lee, Carlo DeAngelis, Allison Jocko, Flay Charbonneau, Katie Wang, Mark Pasetka, Yoo-Joung Ko, Henry C. Y. Wong, Adrian Wai Chan, Thenugaa Rajeswaran, Milena Gojsevic, Edward Chow, Richard J. Gralla, Terry L. Ng, Katarzyna J. Jerzak

Published in: Supportive Care in Cancer | Issue 5/2024

Abstract

Chemotherapy-induced nausea and vomiting (CINV) is a common toxicity that may impair the quality of life of patients with various malignancies ranging from early to end stages. In light of frequent changes to the guidelines for optimal management of CINV, we undertook this narrative review to compare the most recent guidelines published by ASCO (2020), NCCN (2023), MASCC/ESMO (2023), and CCO (2019). The processes undertaken by each organization to evaluate existing literature were also described. Although ASCO, NCCN, MASCC/ESMO, and CCO guidelines for the treatment and prevention of CINV share many fundamental similarities, the literature surrounding low and minimal emetic risk regimens is lacking. Current data regarding adherence to these guidelines is poor and warrants further investigation to improve care.

Coates A, Abraham S, Kaye SB et al (1983) On the receiving end—patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 19:203–208CrossRefPubMed

Vardy JL, Liew A, Warby A et al (2022) On the receiving end: have patient perceptions of the side-effects of cancer chemotherapy changed since the twentieth century? Support Care Cancer 30:3503–3512CrossRefPubMedPubMedCentral

Kuchuk I, Bouganim N, Beusterien K et al (2013) Patient perceptions about potential side effects and benefits from chemotherapy agents. J Clin Oncol 31:6595–6595CrossRef

Matzka M, Köck-Hódi S, Jahn P et al (2018) Relationship among symptom clusters, quality of life, and treatment-specific optimism in patients with cancer. Support Care Cancer 26:2685–2693CrossRefPubMedPubMedCentral

Grunberg SM, Warr D, Gralla RJ et al (2011) Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—state of the art. Support Care Cancer 19:S43–S47CrossRefPubMed

Navari RM (2015) Treatment of breakthrough and refractory chemotherapy-induced nausea and vomiting. Biomed Res Int 2015:595894–595896CrossRefPubMedPubMedCentral

Navari RM, Ruddy KJ, Leblanc TW et al (2019) Impact of addition of carboplatin AUC <= 4 to antiemetic guidelines for triple antiemetic prophylaxis: a gap in quality of care, guideline adoption, and avoiding acute care. Proc Am Soc Clin Oncol 16:e132–e138

Gao J, Zhao J, Jiang C et al (2022) Olanzapine (5 mg) plus standard triple antiemetic therapy for the prevention of multiple-day cisplatin hemotherapy-induced nausea and vomiting: a prospective randomized controlled study. Support Care Cancer 30:6225–6232CrossRefPubMedPubMedCentral

Razvi Y, Chan S, McFarlane T et al (2019) ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients. Support Care Cancer 27:87–95CrossRefPubMed

10.

Hesketh PJ, Kris MG, Basch E et al (2020) Antiemetics: ASCO guideline update. J Clin Oncol 38:2782–2797CrossRefPubMed

11.

Hesketh PJ, Kris MG, Basch E et al (2017) JOURNAL OF CLINICAL ONCOLOGY Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 35:3240–3261CrossRefPubMed

12.

Berger MJ, Agarwal R, Anand S et al (2023) NCCN guidelines version 1.2023 antiemesis continue, https://www.nccn .

13.

Summary of 2019 antiemetic recommendations. 2019

14.

Dupuis LL, Sung L, Molassiotis A et al (2017) 2016 updated MASCC/ESMO consensus recommendations: prevention of acute chemotherapy-induced nausea and vomiting in children. Support Care Cancer 25:323–331CrossRefPubMed

15.

Molassiotis A, Lou AM, Fleury M et al (2023) MASCC/ESMO consensus antiemetic guidelines related to integrative and non-pharmacological therapies. Support Care Cancer 2023(32):30

16.

Olver I, Clark-Snow R, Ruhlmann CH et al (2024) 2023 updated MASCC/ESMO consensus recommendations: controlling nausea and vomiting with chemotherapy of low or minimal emetic potential. Support Care Cancer 32:37CrossRef

17.

Rapoport BL, Herrstedt J, Snow RC et al (2024) 2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer 32:36CrossRef

18.

Scotté F, Schwartzberg L, Lihara H et al (2024) 2023 updated MASCC/ESMO Consensus recommendations: prevention of nausea and vomiting following moderately emetic risk antineoplastic agents. Supportive Care in Cancer 32:45CrossRef

19.

Herrstedt J, Celio L, Hesketh P, et al (2024) 2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents. Supportive Care in Cancer 32. https://doi.org/10.1007/s00520-023-08221-4

20.

Jordan K, Gralla R, Rizzi G et al (2016) Efficacy benefit of an NK1 receptor antagonist (NK1RA) in patients receiving carboplatin: supportive evidence with NEPA (a fixed combination of the NK1 RA, netupitant, and palonosetron) and aprepitant regimens. Support Care Cancer 24:4617–4625CrossRefPubMed

21.

Hashimoto H, Abe M, Tokuyama O et al (2020) Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21:242–249CrossRefPubMed

22.

Vimolchalao V, Sakdejayont S, Wongchanapai P et al (2020) The efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Int J Clin Oncol 25:396–402CrossRefPubMed

23.

Navari RM, Qin R, Ruddy KJ et al (2016) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 375:134–142CrossRefPubMedPubMedCentral

24.

Bajpai J, Kapu V, Rath S et al (2024) Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial. Lancet Oncol. https://doi.org/10.1016/S1470-2045(23)00628-9

25.

Zhao Y, Yang Y, Gao F et al (2022) A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study). EClinicalMedicine 55. https://doi.org/10.1016/j.eclinm.2022.101771

26.

Jeon SY, Han HS, Bae WK et al (2019) A randomized, double-blind, placebo-controlled study of the safety and efficacy of olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: results of the Korean South West Oncology Group (KSWOG) study. Cancer Res Treat 51:90–97CrossRefPubMed

27.

Ng TL, Hutton B, Clemons M (2015) Chemotherapy-induced nausea and vomiting: time for more emphasis on nausea? Oncologist 20:576–583CrossRefPubMedPubMedCentral

28.

Hernandez Torres C, Mazzarello S, Ng T et al (2015) Defining optimal control of chemotherapy-induced nausea and vomiting—based on patients’ experience. Support Care Cancer 23:3341–3359CrossRefPubMed

29.

Ng T, Mazzarello S, Wang Z et al (2016) Choice of study endpoint significantly impacts the results of breast cancer trials evaluating chemotherapy-induced nausea and vomiting. Breast Cancer Res Treat 155:337–344CrossRefPubMed

30.

Hutton B, Clemons M, Mazzarello S et al (2015) Identifying an optimal antiemetic regimen for patients receiving anthracycline and cyclophosphamide-based chemotherapy for breast cancer—an inspection of the evidence base informing clinical decision-making. Cancer Treat Rev 41:951–959CrossRefPubMed

31.

Yamamoto S, Iihara H, Uozumi R et al (2021) Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials. BMC Cancer 21:832CrossRefPubMedPubMedCentral

32.

Radhakrishnan V, Joshi A, Ramamoorthy J et al (2019) Intravenous fosaprepitant for the prevention of chemotherapy-induced vomiting in children: a double-blind, placebo-controlled, phase III randomized trial. Pediatr Blood Cancer 66:e27551CrossRefPubMed

33.

Food and Drug Administration (2019) Highlights of prescribing information: EMEND (fosaprepitant) for injection, for intravenous use, www.fda.gov/medwatch

34.

Aapro M, Scotté F, Escobar Y et al (2021) Practice patterns for prevention of chemotherapy-induced nausea and vomiting and antiemetic guideline adherence based on real-world prescribing data. Oncologist 26:e1073–e1082CrossRefPubMedPubMedCentral

35.

Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. Journal of Supportive Oncology 9:188–195CrossRefPubMed

36.

McKinnon K, Jupp J, Ghosh S et al (2019) Adherence to pediatric acute chemotherapy-induced nausea and vomiting guidelines in Canadian hospitals. Pediatr Blood Cancer 66:e27488CrossRefPubMed

37.

Kacar M, MacDonald P, Gibson P (2023) Addressing adherence to guidelines on prevention of acute chemotherapy-induced nausea and vomiting in pediatric patients. Pediatr Blood Cancer 70:e30210CrossRefPubMed

Title: 2020 ASCO, 2023 NCCN, 2023 MASCC/ESMO, and 2019 CCO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in cancer patients
Authors: Samantha K. F. Kennedy
Shannon Goodall
Shing Fung Lee
Carlo DeAngelis
Allison Jocko
Flay Charbonneau
Katie Wang
Mark Pasetka
Yoo-Joung Ko
Henry C. Y. Wong
Adrian Wai Chan
Thenugaa Rajeswaran
Milena Gojsevic
Edward Chow
Richard J. Gralla
Terry L. Ng
Katarzyna J. Jerzak
Publication date: 01-05-2024
Publisher: Springer Berlin Heidelberg
Keywords: Olanzapine
Nausea
Cytostatic Therapy
Vomiting
Dexamethasone
Published in: Supportive Care in Cancer / Issue 5/2024
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-024-08462-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2024

Financial difficulties experienced by patients with gastrointestinal stromal tumours (GIST) in the Netherlands: data from a cross-sectional multicentre study

Effects of taxane-induced peripheral neuropathy on hand dexterity impairment: evaluation of quantitative and subjective assessments

Adherence to dietary guidelines and associated factors among rural Australian cancer survivors: a cross-sectional study

A qualitative study on experiences of stigma among postoperative oral cancer patients

Effect of radiotherapy on the surface roughness and microhardness of contemporary bioactive restorative materials

Correlation between changes in nutritional status and tumor response in patients receiving immunotherapy for lung cancer (NUTIMMUNO study)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer